What this band has actually done:
stocks scoring 0–25
beat the S&P 500 over the next three months
39.9%
of the time, across 100,496 cases
since 2015.
That is below a coin flip — and so is every other band, because the
median stock loses to a cap-weighted index.
How we measured this
Hedge funds
39
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$14.1B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NasdaqGS
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement…
Who's behind the signal
Every informed buyer we can see on NBIX, across all three feeds.
No significant Form 4 insider activity in the window.
Congressional trades · 5 on record
Disclosures from 2020-07-21 to 2025-06-17
The newest disclosure we hold for this stock is 2025-06-17.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
Not a model pick — but on our radar.
NEUROCRINE BIOSCIENCES INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
0
New positions
3
Increasing
5
Decreasing
0
Unchanged
Price History
Loading price data...
▲
A member of Congress bought
▼
A member sold
Return: High: Low:
Markers sit on the transaction date the member disclosed, snapped to the
nearest close on the chart. They are not the date the public found out — that
came later, and
the gap is its own page.
Every marker is listed by name in the table above.
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to NEUROCRINE BIOSCIENCES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NEUROCRINE BIOSCIENCES INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
ESC
Type to search across stocks, 50 investors & Congress.